Rosetta (mile)stones

Rosetta gets more clinical-stage assets with secondary purchase from pharma VC

Rosetta (mile)stones

Rosetta Capital Ltd.'s latest secondary equity acquisition fits into the firm's wheelhouse because the deal includes clinical-stage companies with upcoming catalysts.

Last week, the London life sciences venture firm

Read the full 298 word article

How to gain access

Continue reading with a
two-week free trial.